Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
The conclusions of a recent study of mitoxantrone (Novantrone) in multiple sclerosis and the approval of several health authorities support its use in patients with active relapsing-remitting or secondary progressive multiple sclerosis. This drug profile provides an outline on relevant preclinical and clinical studies, discusses relevant side effects of the compound and places mitoxantrone in the context of other therapeutic approaches available against this disabling disorder.
Neuhaus
Oliver
O
Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D 40225 Düsseldorf, Germany. oliver.neuhaus@uni-duesseldorf.de
Kieseier
Bernd C
BC
Hartung
Hans-Peter
HP
D000818:Animals; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D008942:Mitoxantrone